お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
市場調査レポート
商品コード
968701

多嚢胞性卵巣症候群治療市場 - 医薬品クラス・流通チャネル・地域別:市場規模・シェア・展望・機会・分析 (2020-2027年)

Polycystic Ovary Syndrome Treatment Market, By Drug Class, By Distribution Channel, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

出版日: | 発行: Coherent Market Insights | ページ情報: 英文 177 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.53円
多嚢胞性卵巣症候群治療市場 - 医薬品クラス・流通チャネル・地域別:市場規模・シェア・展望・機会・分析 (2020-2027年)
出版日: 2020年09月14日
発行: Coherent Market Insights
ページ情報: 英文 177 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、世界の多嚢胞性卵巣症候群治療市場について調査し、市場の概要、市場動向、市場に影響を及ぼす要因の分析、需要分析、各セグメント・地域別の市場分析、価格分析、主要企業のプロファイルなどを提供しています。

目次

第1章 イントロダクション

第2章 市場の展望

  • レポートの説明
    • 市場の定義と範囲
  • エグゼクティブサマリー
    • 市場内訳:医薬品クラス別
    • 市場内訳:流通チャネル別
  • コヒーレントオポチュニティマップ(COM)

第3章 市場力学、規制、および動向分析

  • 市場力学
    • 促進要因
    • 抑制要因
    • 市場機会
  • 影響分析
  • 主な発展
  • 規制シナリオ
  • PEST分析
  • COVID-19影響分析

第4章 世界の多嚢胞性卵巣症候群治療市場:医薬品クラス別

  • イントロダクション
    • 市場シェア分析(%)
    • 前年比成長分析
    • セグメント動向
  • 経口避妊薬
    • イントロダクション
    • 市場規模と予測、および前年比成長率
    • セグメント動向
  • インスリン抵抗性改善薬
  • 抗うつ剤
  • オルニチンデカルボキシラーゼ阻害剤
  • アロマターゼ阻害剤・SERM
  • 利尿薬

第5章 世界の多嚢胞性卵巣症候群治療市場:流通チャネル別

  • イントロダクション
    • 市場シェア分析(%)
    • 前年比成長分析
    • セグメント動向
  • 病院薬局
    • イントロダクション
    • 市場規模と予測、および前年比成長率
    • セグメント動向
  • 小売薬局
  • オンライン薬局

第6章 世界の多嚢胞性卵巣症候群治療市場:地域別

  • イントロダクション
    • 市場シェア分析(%)
    • 前年比成長分析
    • セグメント動向
  • 北米
    • イントロダクション
    • 市場規模と予測、および前年比成長率
  • 米国
  • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • フランス
    • スペイン
    • ロシア
    • その他欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • ASEAN
    • オーストラリア
    • 韓国
    • その他アジア太平洋地域
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
    • その他ラテンアメリカ
  • 中東
    • GCC諸国
    • イスラエル
    • その他中東
  • アフリカ
    • 北アフリカ
    • 中央アフリカ
    • 南アフリカ

第7章 競合情勢

  • 企業プロファイル
    • Sanofi Plc
    • Novartis AG
    • Teva Pharmaceutical Industries Limited
    • Addex Therapeutics Ltd.
    • BIOCAD
    • Merck & Co., Inc.
    • AstraZeneca plc
    • Bristol Myers Squibb Co.
    • Ferring Pharmaceuticals, Inc.
    • Crinetics Pharmaceuticals, Inc.

第8章 セクション

目次

Title:
Polycystic Ovary Syndrome Treatment Market, By Drug Class (Oral contraceptives, Insulin Sensitizing Agents, Anti-Depressants, Ornithine Decarboxylase Inhibitors, Aromatase Inhibitors & SERMs, Diuretics), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027.

Polycystic ovary syndrome can be explained as set of symptoms such as insulin sensitivity, menstrual regulatory, infertility, acne, and excess body and facial hair, which occurs due to increased levels of male hormone i.e. androgens in females of child-bearing age (15 to 49 years). Polycystic ovary syndrome is an incurable diseases, however, it can be managed by various options such as lifestyle changes, reducing weight, and taking medicines.

Restraints of the Global Polycystic Ovary Syndrome Treatment Market

Major factors hampering the growth of the polycystic ovary syndrome treatment market during the forecast period constitutes of unavailability of FDA approved drugs, and alternative treatment options.

Key features of the study:

  • This report provides in-depth analysis of the global polycystic ovary syndrome treatment market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2020-2027), considering 2019, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
  • It profiles leading players in the global polycystic ovary syndrome treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Sanofi, Novartis AG, Teva Pharmaceutical Industries Limited, Addex Therapeutics Ltd., BIOCAD, Merck & Co., Inc., AstraZeneca plc., Bristol Myers Squibb Co., Ferring Pharmaceuticals, Inc., and Crinetics Pharmaceuticals, Inc.
  • Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global polycystic ovary syndrome treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.

Detailed Segmentation

  • Global Polycystic Ovary Syndrome Treatment Market, By Drug Class:
    • Oral contraceptives
    • Insulin Sensitizing Agents
    • Anti-Depressants
    • Ornithine Decarboxylase Inhibitors
    • Aromatase Inhibitors & SERMs
    • Diuretics
  • Global Polycystic Ovary Syndrome Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Polycystic Ovary Syndrome Treatment Market, By Geography:
    • North America
  • By Drug Class
    • Oral contraceptives
    • Insulin Sensitizing Agents
    • Anti-Depressants
    • Ornithine Decarboxylase Inhibitors
    • Aromatase Inhibitors & SERMs
    • Diuretics
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Country:
    • U.S.
    • Canada
    • Europe
  • By Drug Class
    • Oral contraceptives
    • Insulin Sensitizing Agents
    • Anti-Depressants
    • Ornithine Decarboxylase Inhibitors
    • Aromatase Inhibitors & SERMs
    • Diuretics
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Country:
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
  • By Drug Class
    • Oral contraceptives
    • Insulin Sensitizing Agents
    • Anti-Depressants
    • Ornithine Decarboxylase Inhibitors
    • Aromatase Inhibitors & SERMs
    • Diuretics
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Country:
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
    • Latin America
  • By Drug Class
    • Oral contraceptives
    • Insulin Sensitizing Agents
    • Anti-Depressants
    • Ornithine Decarboxylase Inhibitors
    • Aromatase Inhibitors & SERMs
    • Diuretics
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Middle East:
  • By Drug Class
    • Oral contraceptives
    • Insulin Sensitizing Agents
    • Anti-Depressants
    • Ornithine Decarboxylase Inhibitors
    • Aromatase Inhibitors & SERMs
    • Diuretics
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Country:
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
  • By Drug Class
    • Oral contraceptives
    • Insulin Sensitizing Agents
    • Anti-Depressants
    • Ornithine Decarboxylase Inhibitors
    • Aromatase Inhibitors & SERMs
    • Diuretics
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Country/Region:
    • Central Africa
    • South Africa
    • North Africa
  • Company Profiles
    • Sanofi Plc*
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Key Strategies
  • Recent Developments
    • Novartis AG
    • Teva Pharmaceutical Industries Limited
    • Addex Therapeutics Ltd.
    • BIOCAD
    • Merck & Co., Inc.
    • AstraZeneca plc.
    • Bristol Myers Squibb Co.
    • Ferring Pharmaceuticals, Inc.
    • Crinetics Pharmaceuticals, Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

    • Research Objectives
    • Assumptions
    • Abbreviations

2. Market Purview

    • Report Description
  • Market Definition and Scope
    • Executive Summary
  • Market Snippet, By Drug Class
  • Market Snippet, By Distribution Channel
    • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

    • Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
    • Impact Analysis
    • Key Developments
    • Regulatory Scenario
    • PEST Analysis
    • COVID-19 Impact Analysis

4. Global Polycystic Ovary Syndrome Treatment Market, By Drug Class, 2019 - 2027 (US$ Mn)

    • Introduction
  • Market Share Analysis, 2019 and 2027 (%)
  • Y-o-Y Growth Analysis, 2017-2027
  • Segment Trends
    • Oral contraceptives
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Segment Trends
    • Insulin Sensitizing Agents
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Segment Trends
    • Anti-Depressants
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Segment Trends
    • Ornithine Decarboxylase Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Segment Trends
    • Aromatase Inhibitors & SERMs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Segment Trends
    • Diuretics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Segment Trends

5. Global Polycystic Ovary Syndrome Treatment Market, By Distribution Channel, 2019 - 2027 (US$ Mn)

    • Introduction
  • Market Share Analysis, 2019 and 2027 (%)
  • Y-o-Y Growth Analysis, 2017-2027
  • Segment Trends
    • Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)

6. Global Polycystic Ovary Syndrome Treatment Market, By Regions, 2019 - 2027 (US$ Mn)

    • Introduction
  • Market Share Analysis, 2019 and 2027 (%)
  • Y-o-Y Growth Analysis, 2017-2027
  • Segment Trends
    • North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • U.S.
    • Canada
    • Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
    • Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • North Africa
    • Central Africa
    • South Africa

7. Competitive Landscape

    • Company Profiles
  • Sanofi Plc
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Novartis AG
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Teva Pharmaceutical Industries Limited
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Addex Therapeutics Ltd.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • BIOCAD
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Merck & Co., Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • AstraZeneca plc
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bristol Myers Squibb Co.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Ferring Pharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Crinetics Pharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

8. Section

    • References
    • Research Methodology
    • About us and Sales Contact
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.